Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antibe Therapeutics Inc. (V:ATE)

Business Focus: Bio Therapeutic Drugs

Jan 13, 2020 07:00 am ET
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for our overall drug platform.
Nov 28, 2019 07:00 am ET
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.
Aug 27, 2019 07:45 pm ET
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The Company’s unaudited fiscal Q1 2020 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Aug 27, 2019 07:00 am ET
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The clinical study commenced in March 2019 and is designed to validate the efficacy of ATB-346 in reducing pain and establish the dose for Phase 3 development. A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg.
Aug 13, 2019 09:06 am ET
Antibe Announces Closing of Public Offering
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced public offering of 26,833,332 units of the Company (the “Units”) at a price of $0.30 per Unit (the “Offering Price”) for aggregate gross proceeds of $8,050,000 (the “Offering”). The Offering was made pursuant to an amended and restated agency agreement effective August 7, 2019 with a syndicate of agents led by Bloom Burton Securities Inc., together with Echelon
Aug 07, 2019 02:39 pm ET
Antibe Therapeutics Announces Filing of Final Short Form Prospectus
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, announces that it has filed a final short form prospectus (the “Final Prospectus”) relating to the Company’s marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Final Prospectus, the Offering will be for a minimum of 23,333,333 Units and up to a maximum of 26,833,333 Units for minimum gross proceeds of $7,000,000 and maximum gross proceeds of $8,050,000.
Jul 25, 2019 06:45 pm ET
Antibe Therapeutics Announces Size of Offering
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, announces that its previously-announced marketed offering (the “Offering”) of units of the Company (the “Units”) will consist of 23,333,333 Units for gross proceeds of $7,000,000. In respect of the foregoing, Antibe today filed an amended and restated preliminary short form prospectus (the “Amended and Restated Preliminary Prospectus”), to amend and restate the preliminary short form prospectus dated July 23, 2019.
Jul 24, 2019 09:30 am ET
IIROC Trading Resumption - ATE
VANCOUVER, July 24, 2019 /CNW/ - Trading resumes in:
Jul 23, 2019 04:00 pm ET
Antibe Therapeutics Announces Offering of Units
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) in connection with a proposed marketed offering of units (the “Units”) of the Company at a price (the “Offering Price”) of $0.30 per Unit (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each
Jul 23, 2019 03:48 pm ET
IIROC Trading Halt - ATE
VANCOUVER, July 23, 2019 /CNW/ - The following issues have been halted by IIROC:
Jul 16, 2019 09:30 pm ET
Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.
Jul 02, 2019 06:00 pm ET
Antibe Therapeutics Announces Results of Annual General and Special Meeting
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including:
Jun 25, 2019 07:00 am ET
Jun 03, 2019 07:00 am ET
Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain. The Company will be targeting post-operative pain as the lead indication for ATB-352, a US$9 billion market that is in desperate need of safer and non-addictive therapies.
May 30, 2019 07:00 am ET
Antibe Therapeutics Announces Upcoming Conference Schedule
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference schedule for the upcoming months.
Apr 26, 2019 07:00 am ET
Antibe Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on Tuesday, April 30 - Wednesday, May 1, 2019 in Toronto, Canada.
Apr 16, 2019 07:00 am ET
Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today highlights that a research article has been published in the British Journal of Pharmacology (“BJP”) on the successful Phase 2B GI safety trial for its lead drug, ATB-346. BJP is considered one of the world’s pre-eminent scientific journals in pharmacology.
Mar 29, 2019 07:00 am ET
Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that its Phase 2B dose-ranging, efficacy study for ATB-346 has formally commenced. Enrollment is open, clinical sites have been activated and patients will now begin screening.
Feb 27, 2019 08:44 am ET
Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced bought deal public offering of 23,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the “Offering Price”) for aggregate gross proceeds of $5,750,000 (the “Offering”), including the exercise in full of the Underwriters’ over-allotment option. The Offering was made pursuant to a
Feb 22, 2019 07:00 am ET
Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been named a 2019 TSX Venture 50™ company, an award that recognizes the top performing companies on the TSX Venture Exchange over the past year. Antibe was ranked second in the Clean Technology and Life Sciences sector.
Feb 15, 2019 07:30 pm ET
Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Feb 04, 2019 04:01 pm ET
Antibe Therapeutics Announces $5 Million Bought Deal Offering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an agreement with Bloom Burton Securities Inc., on behalf of a syndicate of underwriters including Echelon Wealth Partners Inc. and Dominick Capital Corporation (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 20,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the
Feb 04, 2019 03:16 pm ET
IIROC Trading Resumption - ATE
VANCOUVER, Feb. 4, 2019 /CNW/ - Trading resumes in:
Feb 04, 2019 03:01 pm ET
IIROC Trading Halt - ATE
VANCOUVER, Feb. 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 21, 2019 07:00 am ET
Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The primary objective of the study is to evaluate the efficacy of ATB-346 in reducing osteoarthritis (“OA”) pain over a 14-day treatment period. The study will involve a total of 360 patients with OA of the knee, who will be randomized to placebo o
Dec 19, 2018 07:00 am ET
Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has received gross proceeds of $1.6 million from the exercise of warrants. A total of 7,066,001 warrants were exercised at a price of $0.22 with expiries on December 15th and 21st, 2018. Nearly all of the warrants expiring in December 2018 were exercised.
Nov 30, 2018 07:00 am ET
Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been invited to present at the 11th Annual LD Micro Main Event Investor Conference being held December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Nov 27, 2018 07:00 am ET
Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the successful completion of part one of the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The study was conducted in 24 healthy volunteers who were randomized to once daily doses of ATB-346 at 250 mg, 200 mg or 150 mg.
Nov 23, 2018 06:00 pm ET
Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, November 23rd for the fiscal quarter ended September 30, 2018. The Company’s unaudited fiscal Q2 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Oct 22, 2018 07:00 am ET
Antibe Therapeutics Establishes Business Development Advisory Board
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has established a strategic advisory board to support its business development activities.
Oct 10, 2018 07:00 am ET
Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The first part of the study is a metabolism protocol that will be conducted in 24 healthy volunteers over a 7 day treatment period. The primary objective of the protocol is to determine the principle metabolites of ATB-346 in humans and characteri
Oct 03, 2018 05:00 pm ET
Antibe Therapeutics Announces Grant of Restricted Share Units
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that it has granted restricted share units (“RSUs”) pursuant to the Company’s RSU plan that was adopted at the most recent annual shareholder’s meeting on June 25, 2018.
Sep 05, 2018 07:00 am ET
Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. ("Kwang Dong") for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea (the “Region”). Kwang Dong is a major pharmaceutical company in the Region, with net sales in excess of US$600 million and over 500 sales representatives.
Aug 29, 2018 06:45 pm ET
Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29th for the fiscal quarter ended June 30, 2018. The Company’s unaudited fiscal Q1 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Aug 29, 2018 07:30 am ET
Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-346. The study was completed in March 2018 and demonstrated unequivocal superiority in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed NSAID in the United States.
Jul 31, 2018 07:00 am ET
Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to provide an update on its clinical development activities for its lead drug, ATB-346.
Jul 06, 2018 07:15 pm ET
Antibe Completes Share Issuance in Connection with Citagenix Credit Facility
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that further to its release of June 29, 2018, it has issued to Bloom Burton Healthcare Lending Trust (“BBHLT”) 578,572 common shares in the capital of Company (“Common Shares”) at a deemed issue price of $0.385 per Common Share. The Common Shares were issued in connection with the entry by Citagenix Inc. (“Citagenix”), a subsidiary of the Company, into a $2.25 million secured revolving credit facility (the “Credit Facility”) provided by BBHLT to replace and
Jul 03, 2018 07:00 am ET
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary endpoint data from the recent Phase 2B gastrointestinal (“GI”) safety study for its lead drug, ATB-346. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the United States.
Jun 29, 2018 06:37 pm ET
Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, June 29 for the fourth quarter and the year ended March 31, 2018. The Company's audited 2018 consolidated financial statements, MD&A and AIF are available on SEDAR.
Jun 26, 2018 06:00 pm ET
Antibe Therapeutics Announces Results of Annual General and Special Meeting
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday. All resolutions proposed to the shareholders were approved, including:
Jun 04, 2018 07:00 am ET
Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, will be attending the 2018 BIO International Convention (“BIO International”) this week in Boston, Massachusetts. BIO International is the largest biopharma partnering event of the year, attracting over 16,000 leaders and business development executives from 5,000 companies across the globe.
May 29, 2018 07:00 am ET
Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its Chief Scientific Officer, John Wallace, will deliver a lecture at the 5th World Congress on Hydrogen Sulfide in Biology and Medicine. The conference is being held at the Intercontinental Yorkville Hotel in Toronto, Canada from May 31st to June 3rd, 2018.
May 24, 2018 07:00 am ET
Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that a team of researchers at the University of Calgary has identified a key mechanism underlying the ability of certain intestinal bacteria to contribute to the ulceration and inflammation that is characteristic of Crohn’s disease and ulcerative colitis (the two forms of IBD). Moreover, they have demonstrated that novel hydrogen sulfide-releasing drugs can reverse these effects, leading to resolution of the inflammation and healing of inte
Apr 30, 2018 07:00 am ET
Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on May 2 – 3, 2018 in Toronto, Canada.
Apr 26, 2018 07:00 am ET
Antibe Therapeutics Announces CEO Letter to Shareholders
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF):
Apr 11, 2018 08:00 pm ET
Antibe Therapeutics Engages Blaise Group International for Executive Search
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations on a global basis. In connection with the agreement, Antibe has granted Blaise Group 151,515 options to purchase common shares of the Company that will vest upon the suc
Apr 03, 2018 07:00 am ET
Antibe Therapeutics Provides Financial Update
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead drug, reports that the Company now has a significantly augmented balance sheet.
Mar 20, 2018 09:02 am ET
IIROC Trading Resumption - ATE
VANCOUVER, March 20, 2018 /CNW/ - Trading resumes in:
Mar 20, 2018 08:35 am ET
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects o
Mar 19, 2018 02:19 pm ET
IIROC Trading Halt - ATE
VANCOUVER, March 19, 2018 /CNW/ - The following issues have been halted by IIROC:
Mar 13, 2018 10:26 am ET
Antibe Therapeutics Announces No Material Change
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in its February 26th, 2018 press release, the Company anticipates being in a position to report top-line results of the Phase 2b clinical trial of its lead drug, ATB-346, during the week of March 19th, 2018.
Feb 27, 2018 09:45 pm ET
Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Feb 26, 2018 07:00 am ET
Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research Inc. (“Topstone”), is currently performing data validation and analysis. Antibe remains on its previously announced schedule and anticipates being in a position to report top-line results during the week of March 19
Jan 29, 2018 07:00 am ET
Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce that the final subjects have been enrolled and are on treatment in the key Phase 2B double-blind clinical trial of ATB-346. The study is being conducted in 240 healthy volunteers and is designed to demonstrate the unequivocal superiority of ATB-346 in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed nonste
Jan 17, 2018 07:00 am ET
Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that it has engaged Brand Institute, Inc. (“Brand Institute”) to advise on the nonproprietary name for its lead drug candidate, ATB-346.
Nov 28, 2017 10:30 pm ET
Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28th for the fiscal quarter ended September 30, 2017. The Corporation’s unaudited fiscal Q2 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR.
Oct 26, 2017 07:00 am ET
Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc. (“Citagenix”), has been selected by Darby Dental Supply, LLC (“Darby Dental”) to be its supplier of premium bone grafting and tissue regeneration products. Darby Dental has been in operation for nearly 70 years and has established itself as one of the largest and most trusted dental distributors in the United States.
Oct 20, 2017 07:00 am ET
Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the world’s largest pharma trade show and considered the leading international pharmaceutical business and networking event. The event will be held on October 24th – 26th and will host over 42,000 pharma industry professionals from over 150 countries.
May 25, 2017 09:49 am ET
IIROC Trading Resumption - ATE
VANCOUVER, May 25, 2017 /CNW/ - Trading resumes in:
May 24, 2017 02:22 pm ET
IIROC Trading Halt - ATE
VANCOUVER, May 24, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 24, 2017 11:14 am ET
IIROC Trading Resumption - ATE
VANCOUVER, Feb. 24, 2017 /CNW/ - Trading resumes in:
Feb 24, 2017 10:12 am ET
IIROC Trading Halt - ATE
VANCOUVER, Feb. 24, 2017 /CNW/ - The following issues have been halted by IIROC: